PTH suppression by calcitriol does not predict off‐target actions in experimental CKD

• Váldodahkkit: Bruno A. Svajger (Dahkki), Cynthia M. Pruss (Dahkki), Kimberly J. Laverty (Dahkki), Jason G. E. Zelt (Dahkki), Glenville Jones (Dahkki), Martin Kaufmann (Dahkki), Martin Petkovich (Dahkki), Rachel M. Holden (Dahkki), Michael A. Adams (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2020-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Vitamin D receptor agonist (VDRA) therapy for PTH suppression is a mainstay for patients with severe CKD. Calcitriol (1,25‐(OH)2D3) is a former first‐line VDRA in CKD treatment. However, a consequence of its use in CKD is accelerated vascular calcification (VC). An experimental CKD model wa...